StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)

Investment analysts at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued on Thursday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

Check-Cap stock opened at $1.27 on Thursday. Check-Cap has a 52 week low of $1.12 and a 52 week high of $3.94. The stock has a market capitalization of $7.43 million, a P/E ratio of -0.42 and a beta of 0.36. The stock has a 50-day simple moving average of $1.65 and a 200 day simple moving average of $1.97.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.